Más como este
Presentación de resultados del 3T 2026 de Eli Lilly
ESTIMADO71% DE CONFIANZAdentro de 36 díasLilly aún no ha confirmado la fecha (no hay ningún comunicado de "Lilly confirma la fecha y la conferencia telefónica para el tercer trimestre de 2026" a 22 de septiembre de 2026; el del 2T se publicó el 22 de julio para el 5 de agosto). Public.com[2] y Nasdaq[3] indican el informe del 3T como "previsto" para el 29/10/2026 "antes de la apertura del mercado", en línea con el patrón de Lilly (el 3T de 2025 se publicó el 30 de octubre de 2025) y con sus conferencias, que "comenzarán a las 10 a. m. hora del Este": por tanto, 29 de octubre de 2026, 10:00 ET (14:00 UTC), estimado hasta el comunicado de confirmación de Lilly.Se espera que Eli Lilly publique sus resultados del tercer trimestre de 2026 el 29 de octubre, con su habitual conferencia telefónica a las 10:00 h ET. Llega tras elevar su previsión de ingresos para 2026 a 85.000-87.000 millones de dólares, después de que los ingresos del segundo trimestre subieran un 48%, hasta 23.000 millones, impulsados por Mounjaro y Zepbound.0.71La FDA aprueba Inluriyo de Lilly junto a Verzenio para el cáncer de mama con mutación ESR1
CONFIRMADO85% DE CONFIANZAhace 5 díasEl comunicado de Lilly lleva la data "INDIANAPOLIS, 18 de septiembre de 2026" y señala que "anunció hoy que la Administración de Alimentos y Medicamentos de EE. UU. (FDA[4]) ha otorgado la aprobación plena"; el propio aviso de la FDA fija la fecha de aprobación el 18 de septiembre de 2026.Una combinación totalmente oral que duplicó la supervivencia libre de progresión mediana, de 5,5 a 11,1 meses, en pacientes con mutación ESR1 en el ensayo EMBER-3. Es la segunda aprobación de la FDA para Inluriyo en menos de un año.0.65Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
CONFIRMADO88% DE CONFIANZAhace 23 díasThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".[1]Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.$2.9B0.65Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out
ESTIMADO50% DE CONFIANZAdentro de 1,8 añosClinicalTrials.gov[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.0.64Lilly Submits Retatrutide to the FDA for Approval
ESTIMADO3 meses de retraso77% DE CONFIANZAdentro de 189 díasLilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.[1]Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.0.62Lilly inicia la construcción de una planta de Foundayo de 6.500 millones de dólares en Generation Park, Houston
CONFIRMADO84% DE CONFIANZAanteayerEl comunicado de Lilly lleva la fecha "HOUSTON[4], 21 de septiembre de 2026" e indica que Lilly "puso hoy la primera piedra en Houston, Texas[6]"; Community Impact[2] informa de que la ceremonia se celebró el 21 de septiembre.Una planta de 236 acres que fabricará el principio activo de la pastilla para adelgazar Foundayo de Lilly, con más de 600 empleos permanentes y unos 4.000 puestos de construcción. Lilly prevé que esté operativa en 2030.$6.5B0.61Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
CONFIRMADO87% DE CONFIANZAhace 120 díasLilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".[1]Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.$3.8B0.61Maridebart Cafraglutide's Phase 3 Trial in Heart Failure With Preserved Ejection Fraction Reads Out
ESTIMADO50% DE CONFIANZAdentro de 1,8 añosClinicalTrials.gov[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Amgen's phase 3 trial of Maridebart Cafraglutide in heart failure with preserved ejection fraction reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,056 participants. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.0.61Elecoglipron's Phase 3 Trial in Weight Management Reads Out
ESTIMADO50% DE CONFIANZAdentro de 1,9 añosClinicalTrials.gov[1] lists 2028-07-31 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).0.60TSMC's Dresden Fab (ESMC) Starts Production
ESTIMADO73% DE CONFIANZAdentro de 1,3 añosTSMC's[1][6] founding release gives a bound, not a day: "production targeted to begin by the end of 2027"; at the September 2026 topping-out the partners still said production starts in 2027 and Hardwareluxx[3] reported tool installation "bis Ende 2027", after which the first chips follow - so 31 December 2027, estimated.ESMC, TSMC's EUR 10 billion joint venture with Bosch, Infineon and NXP, is due to start production at its Dresden fab by the end of 2027 - Europe's first FinFET-capable foundry, making 28/22nm and 16/12nm chips mainly for cars and industry.€10B0.60TSMC's Dresden Fab (ESMC) Tops Out
CONFIRMADO80% DE CONFIANZAhace 9 díasFocus Taiwan[1]: "A topping out ceremony was held Monday at the site" (dateline Sept. 14, "The ceremony, held on Sept. 14"); dpa's preview gave the time: ESMC "feiert ... am Montag (12.00 Uhr) mit einem Richtfest den Abschluss des Rohbaus" - noon CEST, 10:00 UTC.Twenty-five months after its groundbreaking, ESMC - TSMC's joint venture with Bosch, Infineon and NXP - celebrated the topping-out of its roughly EUR 10 billion chip fab in Dresden, TSMC's first in Europe. The shell is finished; cleanroom fit-out follows, with the first process tools due in the second half of 2027.€10B0.60TSMC Starts Volume Production of 2nm (N2) Chips in Kaohsiung
ESTIMADO73% DE CONFIANZAhace 266 díasTSMC's[1][2] 2nm page says N2 "has started volume production in 4Q25 as planned" and its 2025 annual report that it "entered high volume manufacturing in 4Q'25"; neither names the day, so the quarter's last day stands in.TSMC's first nanosheet-transistor node, N2, entered volume production in the fourth quarter of 2025 as planned, starting at Fab 22 in Kaohsiung, with Fab 20 in Hsinchu as its second 2nm fab.0.59